Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Glucose-dependent Insulinotropic Polypeptide (GIP) and Lipid Metabolism

This study has been completed.
Sponsor:
Information provided by:
Hvidovre University Hospital
ClinicalTrials.gov Identifier:
NCT00999271
First received: October 20, 2009
Last updated: NA
Last verified: October 2009
History: No changes posted

October 20, 2009
October 20, 2009
August 2008
September 2009   (final data collection date for primary outcome measure)
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Glucose-dependent Insulinotropic Polypeptide (GIP) and Lipid Metabolism
On the Role of Glucose-dependent Insulinotropic Polypeptide, GIP, in Postprandial Metabolism in Humans

The aim of this proposal is to examine whether endogenous GIP and exogenous GIP alone and in combination with insulin affect gastric emptying (GE), appetite, energy intake, energy expenditure (EE) and plasma levels of triglycerides (TAG), free fatty acids FFA) and glycerol in man.

Not Provided
Observational
Observational Model: Case Control
Not Provided
Not Provided
Non-Probability Sample

Healthy volunteers

Healthy Subjects
Other: Incretin hormone - Glucose-dependent insulinotropic polypeptide (GIP)

two different dosages:

  • 0.8 pmol/kg/min
  • 1.5 pmol/kg/min for 300 minutes
Healthy subjects
30 healthy subjects without family history of diabetes or gastrointestinal disease, a normal oral glucose tolerance test (OGTT) and no intake of medicine
Intervention: Other: Incretin hormone - Glucose-dependent insulinotropic polypeptide (GIP)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
30
September 2009
September 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Informed oral and written consent
  • Caucasians over the age of 18 years
  • Normal 75 g oral glucose tolerance test (OGTT)
  • Normal blood haemoglobin concentration
  • Normal plasma lipid profile

Exclusion Criteria:

  • First-degree relatives with diabetes and familial hypertriglyceridemia
Male
18 Years to 50 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Denmark
 
NCT00999271
HD-2009-0025
No
University of Copenhagen
Hvidovre University Hospital
Not Provided
Not Provided
Hvidovre University Hospital
October 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP